Anupam Rasayan raises Rs 2,149.824 crore in H1 financing

Anupam Rasayan India Limited raised Rs 2,149.824 crore through Rs 1,680 crore of debentures and Rs 469.824 crore of fresh equity in the half year ended September 30, 2026. The consolidated cash-flow statement recorded net financing inflows of Rs 2,228.292 crore, while total assets reached Rs 11,394.89 crore at period end.

How much did Anupam Rasayan raise in the half year?

Anupam Rasayan reported Rs 2,149.824 crore of identified issuance proceeds in the half year ended September 30, 2026. This consisted of Rs 1,380 crore from optionally convertible debentures, Rs 300 crore from non-convertible debentures and Rs 469.824 crore from a fresh equity issue net of expenses.

The debenture issuances accounted for Rs 1,680 crore of the reported proceeds, compared with no separately disclosed debenture issuance in the corresponding half year ended September 30, 2025. The cash-flow statement does not disclose the coupon, maturity, conversion terms, allotment date or intended use of proceeds for the optionally convertible or non-convertible debentures.

Fresh-equity proceeds increased from Rs 3.917 crore in the half year ended September 30, 2025 to Rs 469.824 crore in the September 2026 half year. The same cash-flow statement also records a Rs 60.718 crore security-premium outflow in 2026, while the comparable prior-year period shows a Rs 366.13 crore security-premium inflow.

How did Anupam Rasayan's balance sheet change by September 2026?

Anupam Rasayan's consolidated total assets increased by Rs 3,382.286 crore to Rs 11,394.89 crore at September 30, 2026 from Rs 8,012.604 crore at March 31, 2026. Total equity rose to Rs 5,047.909 crore from Rs 3,301.839 crore, and non-controlling interest increased to Rs 2,148.391 crore from Rs 1,328.122 crore.

Other equity rose to Rs 4,934.059 crore at September 30 from Rs 3,187.99 crore at March 31, while equity share capital was nearly unchanged at Rs 113.85 crore from Rs 113.848 crore. The filing does not provide a separate reconciliation between the Rs 469.824 crore fresh-equity cash inflow and the movement in share capital and other equity.

Non-current assets rose to Rs 6,214.352 crore from Rs 4,285.096 crore, led by goodwill of Rs 1,693.565 crore against Rs 663.461 crore at March 31. Current assets increased to Rs 5,180.538 crore from Rs 3,727.508 crore, with trade receivables rising to Rs 1,581.579 crore from Rs 959.385 crore and inventories rising to Rs 2,088.705 crore from Rs 1,774.752 crore.

Did borrowings rise after Anupam Rasayan issued debentures?

Anupam Rasayan's reported current and non-current borrowings increased by Rs 643.293 crore to Rs 2,457.948 crore at September 30, 2026 from Rs 1,814.655 crore at March 31, 2026. Non-current borrowings were Rs 852.999 crore and current borrowings were Rs 1,604.949 crore at the half-year date.

The movement in reported borrowings was smaller than the Rs 1,680 crore of debenture issuance because the financing statement contains other borrowing and repayment flows. It records Rs 111.056 crore of net repayments of non-current borrowings, Rs 393.371 crore of net proceeds from other borrowings, and Rs 27.188 crore of buyer's credit or letter-of-credit movements during the half year.

Finance costs in the consolidated statement of profit and loss increased to Rs 105.376 crore for the half year ended September 30, 2026 from Rs 71.64 crore a year earlier. The cash-flow statement separately records Rs 102.124 crore of financial charges, described as interest paid, but does not attribute the period's finance cost or interest payments to individual debentures or facilities.

What cash uses accompanied Anupam Rasayan's financing exercise?

Anupam Rasayan generated net cash of Rs 2,228.292 crore from financing activities in the half year ended September 30, 2026, compared with Rs 18.251 crore in the corresponding 2025 period. Investing activities used Rs 2,317.855 crore, including a Rs 1,687.23 crore adjustment due to consolidation and Rs 383.585 crore for property, plant and equipment and right-of-use assets.

The investing cash flows also included Rs 71.23 crore of loans and advances given, Rs 129.497 crore of non-current deposits or loans given, and Rs 40.714 crore of net cash used on current investments. The filing presents these as separate lines and does not allocate specific debenture or equity proceeds to acquisitions, capital expenditure, deposits, loans or investments.

Net cash generated from operations after direct taxes fell to Rs 303.156 crore from Rs 534.932 crore in the prior-year half. Operating profit before working-capital changes rose to Rs 408.325 crore from Rs 267.012 crore, but cash generated from operations before direct taxes fell to Rs 328.03 crore from Rs 554.507 crore after changes in inventories, receivables, loans, advances and liabilities.

Cash and cash equivalents closed at Rs 633.499 crore in the cash-flow statement, compared with Rs 419.906 crore at the beginning of the year and acquisition date. The balance sheet reported cash and cash equivalents of Rs 633.5 crore at September 30, 2026 and Rs 378.069 crore at March 31, 2026.

How does the Bliss GVS Pharma acquisition affect these figures?

Anupam Rasayan became the ultimate parent and promoter of Bliss GVS Pharma Ltd. after acquiring 5,32,36,264 equity shares representing 50.07% of its paid-up equity share capital. The transaction followed a share purchase agreement dated May 23, 2026 and an open offer, with the acquisition occurring on September 28, 2026.

The acquisition was made through Anupam Rasayan and Mates Visa Consultancy Private Limited, its wholly owned subsidiary acting as a person acting in concert. The filing states that 47.95% was acquired through the subsidiary and 2.12% directly by Anupam Rasayan through the open offer or open market, and consolidated results include the acquiree's profit from acquisition to September 30, 2026.

The group recognised provisional goodwill of Rs 1,022.394 crore for the Bliss GVS Pharma acquisition under Indian Accounting Standard 103, Business Combinations. Valuation of certain identifiable intangible assets, property, plant and equipment and related deferred taxes remains in process, and the group expects to finalise the purchase-price allocation within the applicable measurement period.

The half-year cash-flow statement contains a Rs 1,687.23 crore consolidation adjustment, while non-controlling interest increased by Rs 820.269 crore between March 31 and September 30. These items occurred in the same reporting period as the acquisition, but the filing does not provide a transaction-level reconciliation linking acquisition funding, goodwill, debt issuance and the fresh equity proceeds.

Conclusion

Anupam Rasayan's half-year financing was led by Rs 1,680 crore of debenture issuance and supplemented by Rs 469.824 crore of fresh equity. Net financing cash inflows of Rs 2,228.292 crore accompanied higher assets, equity, non-controlling interest and borrowings at September 30, while investing cash outflows of Rs 2,317.855 crore exceeded net operating cash generation of Rs 303.156 crore.

The next disclosed matter to watch is finalisation of the purchase-price allocation for Bliss GVS Pharma, including valuations of identifiable intangible assets, property, plant and equipment and deferred taxes underlying the provisional Rs 1,022.394 crore goodwill. Future filings may also provide further accounting or instrument details for the Rs 1,380 crore optionally convertible debentures and Rs 300 crore non-convertible debentures.